Normal-weight Diabetes: Adipocyte-directed Therapy With Pioglitazone or Tirzepatide
Stanford University
104 participants
Jan 13, 2025
INTERVENTIONAL
Conditions
Summary
This study is to investigate how adipocyte (fat cell) function and fat distribution differ between individuals with normal-weight type 2 diabetes (NWD), those with overweight type 2 diabetes (OWD), and normal-weight controls without diabetes (NWC). The study will assess whether adipocyte-directed therapies, specifically pioglitazone and tirzepatide, can improve insulin resistance, adipocyte function, and fat distribution in individuals with NWD. By analyzing the biological mechanisms underlying adipocyte dysfunction, the study aims to provide insights into novel treatment strategies for improving metabolic health in normal-weight individuals with type 2 diabetes.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Steady state Plasma Glucose test
Will collect 5 blood draws during the test to measure insulin secretion
Needle biopsy to gather a sample of abdominal subcutaneous fat
Whole body DXA scan
Abdominal MRI
Spectroscopy of the abdominal region
16 weeks started at 2.5mg/week and increased to 5mg/week dose
16 weeks at a 45mg/day dose
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06657209